This is true for the Bcl-2 inhibitor venetoclax that is used in routine treatment in combination with azacitidine [19,20,21,22,23,24]; this treatment is associated with decreased responsiveness in monocytic and possibly also erythroid/megakaryocytic AML [19,21,22,23]. The gene discussed is BCL2; the disease is acute myeloid leukemia.